Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Treatment of Adrenal Disorders

Addison's Disease Treatment

  • The American College of Internal Medicine recommends hydrocortisone or cortisone acetate as the preferred glucocorticoid treatment, given in divided doses to mimic the natural circadian rhythm 1, 2, 3
  • Standard starting doses are 15-25 mg/day of hydrocortisone or 20-30 mg/day of cortisone acetate, divided into 2-3 doses with the largest dose in the morning 1
  • The Endocrine Society suggests that monitoring is primarily clinical, as plasma ACTH and serum cortisol are not useful parameters for dose adjustment 1
  • Signs of over-replacement include weight gain, insomnia, and peripheral edema, while under-replacement presents with lethargy, nausea, poor appetite, weight loss, and increased pigmentation 3
  • Patients must be educated on increasing steroid doses during illness or injury and trained in intramuscular hydrocortisone administration during adrenal crisis 1
  • All patients should wear a Medic Alert bracelet and carry a steroid card to inform medical personnel of their condition 1, 3
  • Immediate administration of hydrocortisone is critical in emergency situations to prevent mortality 1
  • Sodium chloride supplementation is often needed to compensate for increased renal sodium loss 1
  • Regular clinical assessment focusing on energy levels, mental concentration, pigmentation changes, and weight is necessary for patients with Addison's disease 1, 3
  • Annual monitoring should include serum sodium and potassium, thyroid function tests, plasma glucose, HbA1c, complete blood count, and vitamin B12 levels, although this recommendation is from Praxis Medical Insights, a similar recommendation is not found in other sources 6

Cushing's Syndrome Treatment

  • The National Comprehensive Cancer Network recommends that treatment approach depends on whether the cause is ACTH-dependent or ACTH-independent 4, 5
  • For pituitary tumors (Cushing's disease), surgical removal of the tumor is first-line treatment 4
  • For ectopic ACTH-producing tumors, surgical removal of the tumor when possible is recommended 4
  • If the primary tumor is unresectable, options include bilateral laparoscopic adrenalectomy or medical management 4, 5
  • Octreotide may be considered for ectopic Cushing's syndrome if the tumor is Octreoscan-positive, though it may be less effective in controlling ACTH secretion 5
  • For benign adrenal tumors, laparoscopic adrenalectomy with postoperative corticosteroid supplementation until HPA axis recovery is recommended 4, 5
  • For malignant adrenal tumors, open adrenalectomy with imaging to evaluate for metastases is necessary 4, 5
  • Adrenostatic agents including ketoconazole and mitotane are used to manage hypercortisolism 4, 5
  • Ketoconazole is most commonly used due to its availability and relatively tolerable toxicity profile 5
  • Symptomatic management of complications like hypertension, hyperglycemia, hypokalemia, and muscle atrophy may be required 4
  • Monitoring depends on treatment approach but focuses on normalization of cortisol levels 4
  • Post-surgical patients require monitoring for adrenal insufficiency and may need temporary glucocorticoid replacement 4, 5
  • Patients on medical therapy require monitoring of drug levels and side effects 5
  • Malignancy should be suspected if the adrenal tumor is larger than 5 cm, has irregular margins, or shows local invasion 4, 5
  • Patients with treated Cushing's syndrome often require temporary glucocorticoid replacement after tumor removal until HPA axis recovery 4
  • CYP3A4 is the key enzyme affecting hydrocortisone clearance, and concomitant medications can affect efficacy in Addison's disease patients 1

REFERENCES

4

Diagnostic Approach to Addison's Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

neuroendocrine tumors. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

6

neuroendocrine tumors. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2012